Oyster Point Pharma Inc. (OYST)
NASDAQ: OYST
· Real-Time Price · USD
11.17
0.00 (0.00%)
At close: Dec 30, 2022, 9:00 PM
Company Description
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc.
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States.
The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease.
It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy.
The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Oyster Point Pharma Inc.
| Country | United States |
| IPO Date | Oct 31, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 303 |
| CEO | Dr. Jeffrey Nau |
Contact Details
Address: 202 Carnegie Ctr Ste 109 Princeton, NEW JERSEY United States | |
| Website | https://www.oysterpointrx.com |
Stock Details
| Ticker Symbol | OYST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001720725 |
| CUSIP Number | 69242L106 |
| ISIN Number | US69242L1061 |
| Employer ID | 81-1030955 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey Nau MMS, Ph.D. | Pres, Chief Executive Officer & Director |
| Daniel Lochner M.B.A. | Chief Financial Officer & Chief Bus. Officer |
| Arty Ahmed | Vice President of Investor relations |
| Barry Rosenfeld J.D. | Senior Vice President & Gen. Counsel |
| Dave Benadon | Chief HR Officer |
| Dr. Eric Carlson Ph.D. | Chief Scientific Officer |
| George Donato M.B.A. | Senior Vice President of CMC & Operations |
| Karen Castillo-Paff | Vice President of Communications & PR |
| Loni Da Silva M.S. | Senior Vice President of Regulatory Affairs |
| Raegan A. McClain CCEP, J.D., L.L.M. | Chief Compliance & Privacy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jan 13, 2023 | 15-12G | Filing |
| Jan 13, 2023 | 8-K/A | [Amend] Current Report |
| Jan 13, 2023 | SC 13D/A | [Amend] Filing |
| Jan 09, 2023 | SC 13D/A | [Amend] Filing |
| Jan 05, 2023 | SC 13D/A | [Amend] Filing |
| Jan 05, 2023 | 4 | Filing |
| Jan 04, 2023 | 4 | Filing |
| Jan 04, 2023 | 4 | Filing |